PURPOSE: To determine the effect of the nitric oxide donor, sodium nitroprusside (SNP), and the nitric oxide synthase (NOS) inhibitor, L-nitro-arginine-methylester (L-NAME), on IOP, mean arterial pressure (MAP), pupil diameter (PD), refraction (Rfx), aqueous humor formation (AHF), and outflow facility (OF) in monkeys. METHODS: Monkeys were treated with single or multiple topical treatments of 500 μg SNP or L-NAME to one eye. IOP was determined by Goldmann applanation tonometry, PD with vernier calipers in room light, Rfx by Hartinger coincidence refractometry, AHF by fluorophotometry, and MAP with a blood pressure monitor. OF was determined by two-level constant pressure perfusion following anterior chamber exchange. RESULTS: Following four topical treatments with 500 μg SNP, 30 minutes apart, IOP was significantly decreased from 2 to 6 hours compared with the contralateral control with the maximum IOP reduction of 20% at 3 hours (P < 0.001). PD, Rfx, and AHF were unchanged. Effects on MAP were variable. OF after SNP exchange was significantly increased by 77% (P < 0.05) at 10(-3) M. Topical L-NAME had no effect on IOP, PD, Rfx, or MAP. CONCLUSIONS: Enhancement of nitric oxide concentration at targeted tissues in the anterior segment may be a useful approach for IOP reduction for glaucoma therapy. Additional studies are warranted before conclusions can be made regarding the effect of NOS inhibition on ocular physiology in nonhuman primates.
PURPOSE: To determine the effect of the nitric oxidedonor, sodium nitroprusside (SNP), and the nitric oxide synthase (NOS) inhibitor, L-nitro-arginine-methylester (L-NAME), on IOP, mean arterial pressure (MAP), pupil diameter (PD), refraction (Rfx), aqueous humor formation (AHF), and outflow facility (OF) in monkeys. METHODS: Monkeys were treated with single or multiple topical treatments of 500 μg SNP or L-NAME to one eye. IOP was determined by Goldmann applanation tonometry, PD with vernier calipers in room light, Rfx by Hartinger coincidence refractometry, AHF by fluorophotometry, and MAP with a blood pressure monitor. OF was determined by two-level constant pressure perfusion following anterior chamber exchange. RESULTS: Following four topical treatments with 500 μg SNP, 30 minutes apart, IOP was significantly decreased from 2 to 6 hours compared with the contralateral control with the maximum IOP reduction of 20% at 3 hours (P < 0.001). PD, Rfx, and AHF were unchanged. Effects on MAP were variable. OF after SNP exchange was significantly increased by 77% (P < 0.05) at 10(-3) M. Topical L-NAME had no effect on IOP, PD, Rfx, or MAP. CONCLUSIONS: Enhancement of nitric oxide concentration at targeted tissues in the anterior segment may be a useful approach for IOP reduction for glaucoma therapy. Additional studies are warranted before conclusions can be made regarding the effect of NOS inhibition on ocular physiology in nonhuman primates.
Authors: Valentina Borghi; Elena Bastia; Massimiliano Guzzetta; Valerio Chiroli; Carol B Toris; Minerva R Batugo; Samantha T Carreiro; Wesley K M Chong; David C Gale; David J Kucera; Liu Jia; Ganesh Prasanna; Ennio Ongini; Achim H P Krauss; Francesco Impagnatiello Journal: J Ocul Pharmacol Ther Date: 2010-04 Impact factor: 2.671
Authors: Jason Y H Chang; W Daniel Stamer; Jacques Bertrand; A Thomas Read; Catherine M Marando; C Ross Ethier; Darryl R Overby Journal: Am J Physiol Cell Physiol Date: 2015-06-03 Impact factor: 4.249
Authors: Guorong Li; Sina Farsiu; Stephanie J Chiu; Pedro Gonzalez; Elke Lütjen-Drecoll; Darryl R Overby; W Daniel Stamer Journal: Invest Ophthalmol Vis Sci Date: 2014-03-04 Impact factor: 4.799
Authors: Michael Madekurozwa; W Daniel Stamer; Ester Reina-Torres; Joseph M Sherwood; Darryl R Overby Journal: Am J Physiol Cell Physiol Date: 2021-01-13 Impact factor: 4.249
Authors: Ester Reina-Torres; Michael L De Ieso; Louis R Pasquale; Michael Madekurozwa; Joseph van Batenburg-Sherwood; Darryl R Overby; W Daniel Stamer Journal: Prog Retin Eye Res Date: 2020-11-28 Impact factor: 21.198